The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

• Published in: BMC medicine Vol. 23; no. 1; pp. 197 - 19
• Main Authors: Tseng, Ping-Tao, Zeng, Bing-Yan, Hsu, Chih-Wei, Hung, Chao-Ming, Carvalho, Andre F., Stubbs, Brendon, Chen, Yen-Wen, Chen, Tien-Yu, Lei, Wei-Te, Chen, Jiann-Jy, Su, Kuan-Pin, Shiue, Yow-Ling, Liang, Chih-Sung
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.04.2025; BioMed Central; BMC
• Subjects: Agonists; Alzheimer's disease; Amyotrophic lateral sclerosis; Analysis; Bayesian analysis; Bias; Clinical trials; Degeneration; Dementia; Dementia disorders; Dextrose; Diabetes mellitus; Diabetes therapy; Disease prevention; Drug dosages; Drug therapy; Evidence-based medicine; Frontotemporal dementia; GLP-1 receptor agonist; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor Agonists - pharmacology; Glucagon-Like Peptide-1 Receptor Agonists - therapeutic use; Glucose; Health aspects; Humans; Hypoglycemic agents; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Hypothalamus; Inhibitors; Intervention; Lewy bodies; Medical research; Medicine, Experimental; Meta-analysis; Methods; Multiple sclerosis; Nervous system; Nervous system diseases; Network meta-analysis; Neurodegenerative disease; Neurodegenerative diseases; Neurodegenerative Diseases - drug therapy; Neurodegenerative Diseases - prevention & control; Neurology; Neuroprotection; Parkinson's disease; Pharmacodynamics; Pharmacology; Randomized Controlled Trials as Topic; Receptors; Risk; Sensitivity analysis; SGLT2 inhibitor; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Taiwan; Neurodegenerative disease; Network meta-analysis; GLP-1 receptor agonist; SGLT2 inhibitor; Parkinson’s disease

Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a new generation of antihyperglycemic agents that operate through mechanisms distinct from conventional diabetes treatments. Beyond their metabolic effects, these medications have demons...